2nd Structure-Based Drug Design Summit Revere Hotel Boston Common, Boston

With tightening budgets and increasing pressure to de-risk R AND D, pharma and biotech are shifting their focus toward smarter, more efficient drug design. Companies are investing more in enabling technologies-from computational modeling and AI-driven predictions to structural biology techniques like Cryo-EM, NMR, and X-ray crystallography-to improve rational drug design and enhance decision-making early in discovery.

While AI-powered structure prediction is transforming the landscape-recognized by the 2024 Nobel Prize for Google DeepMind’s AlphaFold2- its true impact depends on experimental validation. The ability to integrate computational insights with high-resolution structural data is now essential for unlocking complex targets and accelerating drug discovery.